The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024 The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024
Read the original:
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
– In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks –
Read this article:
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
REHOVOT, Israel and WASHINGTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced the appointment of Neal Curran as Chief Business Officer. Mr. Curran joins Biolojic Design with extensive experience in business development in the biopharmaceutical industry and comes to the company as it expands its business and development activities in the U.S.
Read the rest here:
Biolojic Design Appoints Neal Curran as Chief Business Officer
Presentations include first reporting of data for the RESET™ Clinical Trial evaluating SPRINT PNS versus Standard Interventional Management for low back pain Presentations include first reporting of data for the RESET™ Clinical Trial evaluating SPRINT PNS versus Standard Interventional Management for low back pain
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Redhook Ale Brewery (“Redhook”), Seattle’s pioneering craft brewery and a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), officially presents their new partnership with the Montlake Futures NIL Collective, supporting student-athletes at the University of Washington (UW). Together, they launched Montlake Gameday Gold Lager, the Official Beer of the Montlake Futures NIL Collective. This unique lager stands out as the only beer dedicated to supporting UW student athletes.
LJUBLJANA, Slovenia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Protein Evolution, a pioneer in enzyme-driven plastics recycling, has announced a collaboration with Acies Bio, an innovative biotechnology company specializing in microbial R&D and biomanufacturing. This partnership aims to leverage Acies Bio’s state-of-the-art SmartRoute™ platform to scale the production of Protein Evolution’s plastic-degrading enzymes, bringing the world one step closer to a future free from plastic waste.
Read the original post:
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance Biological Recycling Technology
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf therapies that aim to realize the full reach and promise of CAR T-cells, today announced that Scott Myers has been appointed as Chairman of its Board of Directors, succeeding Dieter Weinand who will remain as an advisor.
More here:
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors
Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit
Read more from the original source:
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis...
IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (“GERD”), Crohn’s Disease, and Ulcerative Colitis using its proprietary inFoods® Technology. These patents apply to countries under the European Patent Organization (“EPO”), including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations within the EPO.
See the original post:
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics